Cognitive and Clinical Neuroimaging Core (CCNC), McLean Hospital, 115 Mill St, Belmont, MA, 02478, USA.
Marijuana Investigations for Neuroscientific Discovery (MIND) Program, McLean Hospital, 115 Mill St, Belmont, MA, 02478, USA.
Sci Rep. 2023 Apr 11;13(1):5869. doi: 10.1038/s41598-023-32671-9.
Increasing numbers of individuals have access to cannabinoid-based products containing various amounts of delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and other cannabinoids. Exposure to specific cannabinoids likely influences outcomes; however, current methods for quantifying cannabis exposure do not account for the cannabinoid concentrations of the products used. We developed CannaCount, an examiner-driven metric that quantifies estimated maximum possible cannabinoid exposure by accounting for variables related to cannabinoid concentration, duration, frequency, and quantity of use. To demonstrate feasibility and applicability, CannaCount was used to quantify estimated maximum THC and CBD exposure in 60 medical cannabis patients enrolled in a two-year, longitudinal, observational study. Medical cannabis patients reported using a variety of product types and routes of administration. Calculating estimated exposure to THC and CBD was possible for the majority of study visits, and the ability to generate estimated cannabinoid exposure improved over time, likely a function of improved product labeling, laboratory testing, and more informed consumers. CannaCount is the first metric to provide estimated maximum possible exposure to individual cannabinoids based on actual cannabinoid concentrations. This metric will ultimately facilitate cross-study comparisons and can provide researchers and clinicians with detailed information regarding exposure to specific cannabinoids, which will likely have significant clinical impact.
越来越多的人可以接触到含有不同剂量的 delta-9-四氢大麻酚（THC）、大麻二酚（CBD）和其他大麻素的大麻素产品。接触特定的大麻素可能会影响结果；然而，目前用于量化大麻素暴露的方法并未考虑到所使用产品的大麻素浓度。我们开发了 CannaCount，这是一种由检查者驱动的指标，通过考虑与大麻素浓度、持续时间、频率和使用量相关的变量来量化估计的最大可能大麻素暴露量。为了展示可行性和适用性，我们使用 CannaCount 来量化 60 名参加为期两年的纵向观察性研究的医用大麻患者的估计最大 THC 和 CBD 暴露量。医用大麻患者报告使用了各种产品类型和给药途径。在大多数研究访视中，可以计算 THC 和 CBD 的估计暴露量，并且随着时间的推移，生成估计大麻素暴露量的能力得到了提高，这可能是由于产品标签、实验室测试和更知情的消费者的改进。CannaCount 是第一个根据实际大麻素浓度提供估计的最大单个大麻素暴露量的指标。该指标最终将促进跨研究比较，并为研究人员和临床医生提供有关特定大麻素暴露的详细信息，这可能具有重要的临床影响。
